1. Home
  2. REBN vs MEIP Comparison

REBN vs MEIP Comparison

Compare REBN & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REBN
  • MEIP
  • Stock Information
  • Founded
  • REBN 2015
  • MEIP 2000
  • Country
  • REBN United States
  • MEIP United States
  • Employees
  • REBN N/A
  • MEIP N/A
  • Industry
  • REBN Restaurants
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • REBN Consumer Discretionary
  • MEIP Health Care
  • Exchange
  • REBN Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • REBN 13.5M
  • MEIP 13.3M
  • IPO Year
  • REBN 2022
  • MEIP 2003
  • Fundamental
  • Price
  • REBN $2.88
  • MEIP $2.22
  • Analyst Decision
  • REBN
  • MEIP Hold
  • Analyst Count
  • REBN 0
  • MEIP 1
  • Target Price
  • REBN N/A
  • MEIP N/A
  • AVG Volume (30 Days)
  • REBN 97.6K
  • MEIP 6.0K
  • Earning Date
  • REBN 03-31-2025
  • MEIP 05-13-2025
  • Dividend Yield
  • REBN N/A
  • MEIP N/A
  • EPS Growth
  • REBN N/A
  • MEIP N/A
  • EPS
  • REBN N/A
  • MEIP N/A
  • Revenue
  • REBN $5,928,533.00
  • MEIP N/A
  • Revenue This Year
  • REBN $335.98
  • MEIP N/A
  • Revenue Next Year
  • REBN N/A
  • MEIP N/A
  • P/E Ratio
  • REBN N/A
  • MEIP N/A
  • Revenue Growth
  • REBN 7.63
  • MEIP 33.76
  • 52 Week Low
  • REBN $1.03
  • MEIP $1.46
  • 52 Week High
  • REBN $8.80
  • MEIP $4.10
  • Technical
  • Relative Strength Index (RSI)
  • REBN 47.87
  • MEIP 60.32
  • Support Level
  • REBN $2.46
  • MEIP $2.01
  • Resistance Level
  • REBN $3.45
  • MEIP $2.08
  • Average True Range (ATR)
  • REBN 0.23
  • MEIP 0.10
  • MACD
  • REBN 0.08
  • MEIP 0.03
  • Stochastic Oscillator
  • REBN 45.19
  • MEIP 100.00

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: